IGI Eyes Sustained Momentum: Can Margins Hold as LGD Expands?
International Gemmological Institute enters Q2 FY27 on strong footing after a 31% PAT jump in Q1. The Street expects the company to sustain margin gains and deliver on its full-year guidance—but with the stock at ₹315.15, down 19% from ATH, execution and guidance confidence matter.
What to Expect: Sustaining the Margin Momentum
IGI entered FY27 firing on all cylinders. Q1 delivered 23% revenue growth to ₹371 Cr, 29% EBITDA growth, and a 31% jump in PAT, with EBITDA margin ballooning to 60% (270 basis points wider than year-ago). Management cited broad-based momentum across loose stones, jewelry, and coloured gemstones, plus traction in the US and new operations in Italy. The question for Q2: can IGI sustain this margin beat while keeping revenue growth on the company's 15% FY27 guidance track?
~₹360–400 Cr
15–20% YoY growth; Q1 at ₹371 Cr + 23% YoY. A 15% run-rate for full year implies H1 in the ₹715–750 Cr range.
~58–60%
Q1 at 60%; on-plan would sustain or slightly decline. Margin expansion driver: pricing stability, certification volumes, and LGD mix shift.
~₹150–180 Cr / ₹3.50–4.20
Q1 PAT ₹166 Cr (31% YoY); margin leverage will drive year-on-year growth. EPS at ₹3.80 in Q1.
Certification throughput; LGD ASP
Watch: loose stones certification velocity, LGD vs natural stone mix, and pricing hold in a softer diamond cycle. Italy & US onramp may dilute near-term leverage.
A strong Q2 print would show revenue holding at 18%+ YoY growth (maintaining Q1's momentum), EBITDA margin at or above 59%, and PAT growth north of 25% YoY. Management would likely reaffirm or raise FY27 EBITDA guidance (currently 20%). A weak print would be revenue below 12% growth, margin compression below 57%, or softer LGD demand signals. Watch also for Italy/US investment drag on near-term margins and any commentary on pricing pressure in lab-grown diamonds globally.
Is IGI Tracking Its Full-Year Guidance?
Q1 was a beat vs the 15% FY27 revenue growth guide—management is guiding 15%, but delivered 23% YoY. If Q2 comes in at 15–18% (a deliberate deceleration or normalization), H1 would sit at ~19% growth, still ahead of full-year target. That leaves room for a slowdown in H2 as the comp base gets tougher and international investments mature. The EBITDA guidance of 20% growth (from FY26) is also looking on-track after Q1's 29% jump. However, the margin expansion (EBITDA at 60%, PAT margin at 45%) is front-loaded by strong pricing and mix. Sustain on that is the key test.
The Street's View
Since Last Quarter: The Filings Scan
Oct 12, 2026
Q2 results board meeting scheduled for Oct 21, 2026 (result day). Agenda: approval of unaudited standalone and consolidated results.
Board Meeting Notice
Sep 24, 2026
Trading window closed Oct 1–48 hours post-result for Q2/H1 FY27, per SEBI insider trading norms. Normal precaution; no red flag.
Trading Window Closure
Sep 08, 2026
IGI Botswana became 100% wholly owned subsidiary (finalized Sept 8). Step-down acquisition by IGI Dubai consolidates control. Operational update; expected to be accretive to group earnings.
Botswana Consolidation
Aug 31, 2026
IGI Dubai board approved consolidation of Botswana subsidiary control. Part of African growth strategy.
Botswana Consolidation Approval
Aug 18, 2026
Board approved ₹2.55/share first interim dividend for FY27 (record date Aug 28). Signals confidence in cash generation; no payout ratio concern.
First Interim Dividend
Aug 18, 2026
629,814 stock options granted to employees under the 2024 ESOP plan. Routine talent retention; no dilution concern.
ESOP Grant
Jul 23, 2026
Q1 results published (23% revenue, 31% PAT growth). 28th AGM scheduled for Aug 14, 2026. BRSR (sustainability report) filed.
Q1 Results & AGM Notice
Jul 14, 2026
Manu Sharma appointed Chief Operating Officer and Senior Management Personnel (effective Jul 14). Reinforces operational focus ahead of expansion.
COO Appointment
Jul 23, 2026
Monitoring Agency Report (ICRA) confirmed no deviation in FY26 Q2 IPO proceeds utilization. All funds deployed as per prospectus; no red flag.
IPO Proceeds Monitoring
Key takeaway: No material red flags. The Botswana consolidation aligns with Africa growth strategy. The dividend and ESOP grants signal management confidence and talent retention. The COO appointment (Manu Sharma, Jul 14) reinforces operational maturity. Trading window closure is routine. No promoter pledges, no insider selling, no regulatory concerns—a clean quarter in corporate governance terms.
What to Watch on October 21
1 · Revenue growth rate: Is it 15% or 20%?
Q1 at 23% was ahead of the 15% FY27 guide. A Q2 at 18%+ shows momentum is sustainable; below 12% suggests normalization or demand softening in LGD or coloured gemstones.
2 · EBITDA margin: Can 60% hold?
Q1 at 60% was exceptional. On-plan is 58–60%; below 57% suggests mix dilution (international ops, new markets) outpacing scale benefits. Watch the operational leverage story.
3 · Management's revised FY27 guidance
Reaffirm 15% revenue & 20% EBITDA growth, or raise? If raising, the market rewards; if guiding down, the narrative shifts to normalization post-IPO. Listen for Italy & US commentary.
4 · LGD pricing & certification volume trends
Are loose-stones and jewelry certifications accelerating or flat? Is lab-grown diamond pricing holding, or is there margin pressure? Global gemstone cycle and IGI's mix matter for margins.
IGI is a certification and grading juggernaut riding the Lab-Grown Diamond mega-trend. Q1 proved the business model (31% PAT growth, 60% EBITDA margin). But the stock—down 19% from ATH yet trading 40% below consensus targets—is priced for execution. Q2 results must sustain the margin beat and keep revenue growth within shouting distance of the 15% FY27 guide. Watch the LGD pricing story, the operational leverage from international expansion (Italy, US onramp), and management's tone on full-year guidance. A beat on margins + a raised guide would re-energize the narrative; a miss would shift the debate to cyclicality in gemstones.